Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Stocks: Insiders Buy at Ruby Tuesday, Valeant Pharmaceuticals, and Janus Capital

By

Plus, a purchase at Fibrocell Science.

PrintPRINT
Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:
  • Randal Kirk, a beneficial owner of aesthetic and therapeutic development stage biotechnology company Fibrocell Science (NYSEMKT:FCSC), bought 1,024,590 shares of company stock for $4,999,999. Fibrocell specializes in skin and tissue rejuvenation products.
  • Laizer Kornwasser, Vice President and Chairman of the multinational specialty pharmaceutical company Valeant Pharmaceuticals (NYSE:VRX), bought 2,536 shares of company stock for $335,128.
  • Jeffrey Diermeier, a director at investment management firm Janus Capital (NYSE:JNS), bought 26,000 shares of company stock for $300,056.
  • James Buettgen, CEO of casual dining restaurants company Ruby Tuesday (NYSE:RT), bought 50,000 shares of company stock for $281,400.
For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JB*
$4,999,999
2
CEO,CB,BO
B
$4,709,832
3
DIR
B
$840,000
4
DIR,BO
B
$560,646
5
VP,CB
AB
$335,128
6
DIR
B
$300,056
7
CEO,DIR
B
$281,400
8
PR,DIR
B
$248,129
9
BO
B
$213,378
10
VP
B
$179,160

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
S
$7,539,345
2
CEO,DIR
AS
$5,843,350
3
VP,OO
S
$2,956,581
4
BO
AS
$2,463,868
5
VP
S
$2,384,926
6
CB,CEO
S
$2,379,020
7
PR,OO,VP,DIR
AS
$2,364,844
8
DIR
AS
$1,599,239
9
VP,SO
S
$1,457,082
10
VP,DIR
AS
$1,329,627

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
No positions in stocks mentioned.
PrintPRINT

Busy? Subscribe to our free newsletter!

Submit
 

WHAT'S POPULAR IN THE VILLE